September 4, 2019 / 5:09 AM / 19 days ago

BRIEF-Roche Says Ocrevus MS Drug Data Show Reduction Of Disability Progression

Sept 4 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT PIVOTAL DATA FOR SATRALIZUMAB IN NEUROMYELITIS OPTICA SPECTRUM DISORDER AND SIX-YEAR OCREVUS DATA IN MULTIPLE SCLEROSIS AT ECTRIMS

* INVESTIGATIONAL MEDICINE SATRALIZUMAB SIGNIFICANTLY REDUCES RISK OF RELAPSE IN PIVOTAL SAKURASTAR MONOTHERAPY STUDY FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER

* NEW DATA PROVIDE INSIGHTS INTO NEUROFILAMENT LIGHT CHAIN LEVELS AS A POTENTIAL BIOMARKER FOR PREDICTING MS DISABILITY PROGRESSION Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below